Conditional survival of patients with low-risk prostate cancer: Temporal changes in active surveillance permanence over time.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
07 2023
Historique:
received: 26 09 2022
revised: 05 03 2023
accepted: 14 03 2023
medline: 19 6 2023
pubmed: 22 5 2023
entrez: 21 5 2023
Statut: ppublish

Résumé

To determine risk categories for patients with prostate cancer (PCa) in active surveillance (AS) and to test the conditional survival (CS) that examined the effect of event-free survival since AS-entrance. From January 2012 to December 2020 we analyzed 606 patients with PCa enrolled in our AS program. Kaplan-Meier (KM) plots depicted AS-exit rate. Multivariable Cox regression models (MCRMs) tested for AS-exit rate independent predictors to determine risk categories. CS estimates were used to calculate overall AS-exit rate after event-free survival intervals of 1, 2, 3, and 5 years, and after stratification according to risk categories. At MCRMs PSAd ≥ 0.15 (HR: 1.43; P-value 0.04), PI-RADS 4-5 (HR: 2.56; P-value <0.001) and number of biopsy positive cores ≥ 2 (HR: 1.75; P-value <0.001) were independent predictors of AS-exit. These variables were used to determine risk categories: low-, intermediate- and high-risk. Overall, according to CS-analyses, 5-year AS-exit free rate increased from 59.7% at baseline, to 67.3%, 74.7%, and 89.4% in patients who remained in AS respectively ≥1, ≥2, ≥3 and ≥5 years. After stratification according to risk categories, in those patients who remained in AS ≥ 5 years, 5-year AS-exit free rates increased from 76.3% to 100% in patients with a low-risk, from 62.7% to 83.7% in patients with an intermediate-risk and from 42.3% to 87.5% in patients with a high-risk. CS models showed a direct relationship between event-free survival duration and subsequent AS permanence in overall PCa patients and after stratification according to risk categories.

Identifiants

pubmed: 37211449
pii: S1078-1439(23)00091-1
doi: 10.1016/j.urolonc.2023.03.006
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

323.e1-323.e8

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Authors declare no conflicts of interest, including specific financial interests or relationships or affiliations relevant to the subject matter or materials discussed in the manuscript.

Auteurs

Francesco A Mistretta (FA)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy. Electronic address: francescoalessandro.mistretta@ieo.it.

Stefano Luzzago (S)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.

Sarah Alessi (S)

Department of Radiology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Mattia Piccinelli (M)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Giulia Marvaso (G)

Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy; Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Arturo Lo Giudice (AL)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Marco Nizzardo (M)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Gabriele Cozzi (G)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Matteo Fontana (M)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Giulia Corrao (G)

Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Matteo Ferro (M)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Zhe Tian (Z)

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.

Barbara A Jereczek-Fossa (BA)

Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy; Department of Radiotherapy, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Giuseppe Petralia (G)

Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy; Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

Ottavio de Cobelli (O)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.

Gennaro Musi (G)

Department of Urology, European Institute of Oncology (IEO) IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH